Regulatory authorities and marketing authorisation holders both play an important part in preparing for the consequences of Brexit to safeguard the continuous supply of medicines after the withdrawal of the UK from EU.
The 2018 Global Bio Conference kicked off in Seoul, bringing together biotech regulators and industry experts from around the world to support the growth and overseas expansion of South Korea’s biopharmaceutical businesses.
According to DSM Group, in 2017, the Russian market was worth 1629 billion rubles, which 8% higher than in 2016. For the first time in three years, the market grew in dollar- and euro-denominated terms.
South Korea’s major biopharmaceutical firm Samsung BioLogics Co., which has been embroiled in an alleged violation of accounting rules, expressed concern over the local financial regulator’s disclosure of sensitive information.
The 2017 annual report provides an overview of the work of the European Medicines Agency (EMA) and highlights last year’s major achievements in protecting and promoting public and animal health in the European Union (EU).
The spring English-language issue of «CIS GMP News» reflects the current state of pharmaceutical industry in Russia and other EAEU member states, and highlights achievements in the area of pharmaceutical manufacturing.
The initiative to ban TV advertising of medicines is extremely harmful and dangerous, because it may be motivated by concealed interests of pharmaceutical companies, said Deputy Minister of Communications and Mass Media.
Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced the launch of Sofinnova Crossover I with €275 million, above the original first close target of €250 million.